Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI

Femme et Homme Max 99 ans
IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI MAJ Il y a 4 ans

Phase II Trial of Temozolomide in Patients affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer with MGMT methylation. GOPAV03 Overall response rate [ORR = CR + PR]

Pays Aucun
Organes Aucun
Spécialités Aucune

unknown

Plus d'informations

Femme Max 99 ans
IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI MAJ Il y a 4 ans

A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast cancer • Safety of treatment of the combination of DHEA and an aromatase inhibitor (anastrozole or letrozole or exemestane) in pre-treated post-menopausal metastatic breast cancer patients • Efficacy (eval...

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations